Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025
Seres Therapeutics (NASDAQ: MCRB), a leading live biotherapeutics company, has scheduled its second quarter 2025 financial results and business updates conference call for August 6, 2025, at 8:30 a.m. ET.
The company will host both a conference call and live audio webcast. Investors can access the call by dialing 800-715-9871 (domestic) or 646-307-1963 (international) with conference ID 3641971. The webcast will be available in the "Investors and News" section of the Seres website and will remain archived for approximately 21 days.
Seres Therapeutics (NASDAQ: MCRB), un'azienda leader nel campo dei biofarmaci vivi, ha programmato la conferenza telefonica per la presentazione dei risultati finanziari del secondo trimestre 2025 e gli aggiornamenti aziendali per il 6 agosto 2025 alle 8:30 ET.
L'azienda offrirà sia una conferenza telefonica che una trasmissione audio in diretta via web. Gli investitori potranno partecipare chiamando il numero 800-715-9871 (nazionale) o 646-307-1963 (internazionale) con ID conferenza 3641971. La trasmissione sarà disponibile nella sezione "Investitori e Notizie" del sito di Seres e resterà archiviata per circa 21 giorni.
Seres Therapeutics (NASDAQ: MCRB), una empresa líder en biofármacos vivos, ha programado su llamada de conferencia para los resultados financieros del segundo trimestre de 2025 y actualizaciones comerciales para el 6 de agosto de 2025 a las 8:30 a.m. ET.
La compañía ofrecerá tanto una llamada de conferencia como una transmisión de audio en vivo por internet. Los inversores pueden acceder a la llamada marcando 800-715-9871 (nacional) o 646-307-1963 (internacional) con el ID de conferencia 3641971. La transmisión estará disponible en la sección "Inversores y Noticias" del sitio web de Seres y permanecerá archivada aproximadamente 21 días.
Seres Therapeutics (NASDAQ: MCRB)는 선도적인 생체 치료제 기업으로서 2025년 2분기 재무 결과 및 사업 업데이트 컨퍼런스 콜을 2025년 8월 6일 오전 8시 30분(동부시간)에 예정했습니다.
회사는 컨퍼런스 콜과 라이브 오디오 웹캐스트를 모두 진행할 예정입니다. 투자자들은 국내: 800-715-9871, 국제: 646-307-1963번으로 컨퍼런스 ID 3641971을 입력하여 참여할 수 있습니다. 웹캐스트는 Seres 웹사이트의 "투자자 및 뉴스" 섹션에서 제공되며 약 21일간 아카이브됩니다.
Seres Therapeutics (NASDAQ : MCRB), une entreprise leader dans le domaine des biothérapies vivantes, a programmé sa conférence téléphonique sur les résultats financiers du deuxième trimestre 2025 et les mises à jour commerciales pour le 6 août 2025 à 8h30 ET.
L'entreprise proposera à la fois une conférence téléphonique et une diffusion audio en direct sur le web. Les investisseurs peuvent accéder à l'appel en composant le 800-715-9871 (domestique) ou le 646-307-1963 (international) avec l'ID de conférence 3641971. La diffusion sera disponible dans la section "Investisseurs et Actualités" du site Seres et restera archivée pendant environ 21 jours.
Seres Therapeutics (NASDAQ: MCRB), ein führendes Unternehmen im Bereich lebender Biotherapeutika, hat seine Telefonkonferenz zu den Finanzergebnissen und Geschäftsupdates für das zweite Quartal 2025 für den 6. August 2025 um 8:30 Uhr ET angesetzt.
Das Unternehmen wird sowohl eine Telefonkonferenz als auch einen Live-Audio-Webcast anbieten. Investoren können die Telefonkonferenz unter 800-715-9871 (national) oder 646-307-1963 (international) mit der Konferenz-ID 3641971 erreichen. Der Webcast wird im Bereich "Investoren und Nachrichten" auf der Seres-Website verfügbar sein und etwa 21 Tage archiviert bleiben.
- None.
- None.
CAMBRIDGE, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on August 6, 2025 at 8:30 a.m. ET to discuss second quarter 2025 financial results and provide business updates.
To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 3641971. To join the live webcast, please visit the “Investors and News” section of the Seres website at www.serestherapeutics.com.
A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. Seres led the successful development and approval of VOWST™, the first FDA-approved orally administered microbiome therapeutic, which was sold to Nestlé Health Science in September 2024. The Company is developing SER-155, which has received Breakthrough Therapy designation for the reduction of bloodstream infections in adults undergoing allo-HSCT and Fast Track designation for reducing the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT, and which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT. SER-155 and the Company's other pipeline programs are designed to target multiple disease-relevant pathways and are manufactured from standard clonal cell banks via cultivation, rather than from the donor-sourced production process used for VOWST. In addition to allo-HSCT, the Company intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically vulnerable patient populations including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities. For more information, please visit www.serestherapeutics.com.
Investor and Media Contact:
IR@serestherapeutics.com
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
FAQ
When will Seres Therapeutics (MCRB) report Q2 2025 earnings?
How can investors access the Seres Therapeutics Q2 2025 earnings call?
How long will the MCRB Q2 2025 earnings webcast replay be available?
What topics will be covered in Seres Therapeutics' Q2 2025 conference call?
